Patient Characteristics* | Efavirenz initiators (N = 380) | Atazanavir initiators (N = 281) | P-value** |
---|---|---|---|
Study site | Â | Â | <0.0001 |
Navy | 32% | 25% | Â |
MACS | 33% | 15% | Â |
WIHS | 36% | 60% | Â |
Male | 63% | 38% | <0.0001 |
Race/Ethnicity | Â | Â | <0.0001 |
Caucasian (Hispanic & Non Hispanic) | 43% | 28% | Â |
African-American (Hispanic & Non-Hispanic) | 46% | 49% | Â |
Hispanic (non-white, non-black) & other | 11% | 22% | Â |
Age at switch/initiation | 41 (34, 47) | 41 (35, 46) | 0.91 |
Medical History | Â | Â | Â |
Diabetes Mellitus | 11% | 17% | 0.03 |
Thyroid Disease | 3% | 6% | 0.07 |
Hepatitis C antibody status | 15% | 19% | 0.18 |
Treatment Characteristics | Â | Â | Â |
HAART initiation date | Aug 2001 (Aug 97-Sep03) | Dec 1998 (May 97-Sep 02) | 0.003 |
ART-naïve at initiation | 34% | 12% | <0.0001 |
Class-naïve at initiation | 80% | 30% | <0.0001 |
Years of HAART exposure at initiation | 0.5 (0.1, 2.9) | 3.6 (1.2, 5.7) | <0.0001 |
Atazanavir regimen included Ritonavir | Â | 79% | Â |
HIV biomarkers prior to initiation | Â | Â | Â |
CD4+ cell count | 332 (216, 464) | 289 (202, 462) | 0.11 |
Log10 HIV RNA | 4.15 (2.65, 4.75) | 4.01 (2.59,4.76) | 0.42 |
Viral load <80 copies/mL | 19% | 17% | 0.50 |
Post-initiation HIV characteristics*** | Â | Â | Â |
CD4+ cell count | 434 (303, 581) | 410 (241, 575) | 0.02 |
Log10 HIV RNA | 1.90 (1.90, 2.38) | 1.90 (1.90, 2.51) | <0.0001 |
Viral load <80 copies/mL | 68% | 58% | 0.0003 |
NRTI backbone included | Â | Â | Â |
TDF or ABC & D4T, DDI, or AZT | 19% | 28% | 0.0003 |
   TDF or ABC but not D4T, DDI, or AZT | 32% | 58% | <0.0001 |
   D4T, DDI, or AZT but not TDF or ABC | 49% | 14% | <0.0001 |